Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.40 |
| ▸ | CPA2 | P48052 | 3/20 | 0.40 |
| ▸ | CPA4 | Q9UI42 | 3/20 | 0.40 |
| ▸ | ECE1 | P42892 | 8/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 6/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | IL1RN | P18510 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412346 | 0.93 | CPA1 (0.45) | CPA1CPA2CPA4ECE1ERAP2 | |
| SCHEMBL6917414 | 0.85 | MMP1 (0.41) | CPA1CPA2CPA4CPB1ACE2 | |
| SCHEMBL6417816 | 0.85 | ECE1 (0.40) | CPA1CPA2CPA4ECE1CPB1 | |
| SCHEMBL6412734 | 0.84 | CPA1 (0.39) | CPA1CPA2CPA4ECE1ERAP2 | |
| SCHEMBL6414339 | 0.84 | ECE1 (0.39) | CPA1CPA2CPA4ECE1ERAP2 | |
| SCHEMBL7320171 | 0.82 | CPA1 (0.41) | CPA1CPA2CPA4ECE1ERAP2 | |
| SCHEMBL7321038 | 0.81 | MMP1 (0.49) | — | |
| SCHEMBL7325571 | 0.81 | SLC1A3 (0.45) | ECE1ACE2 | |
| SCHEMBL7324109 | 0.80 | CPA1 (0.39) | CPA1CPA2CPA4ECE1ERAP2 | |
| SCHEMBL27542505 | 0.80 | CPA1 (0.46) | CPA1CPA2CPA4ECE1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993009136-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1993-05-13 | — | — | WO | disclosed |